Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2025-06-25 DOI:10.1111/liv.70192

Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Kosuke Matsui, Atsushi Naganuma, Hironori Tanaka, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Hironori Ochi, Michitaka Imai, Shinichiro Nakamura, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

{"title":"Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study","authors":"Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Kosuke Matsui, Atsushi Naganuma, Hironori Tanaka, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Hironori Ochi, Michitaka Imai, Shinichiro Nakamura, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)","doi":"10.1111/liv.70192","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>This study aimed to evaluate the therapeutic efficacy and prognostic significance of C-reactive protein (CRP) in patients with advanced hepatocellular carcinoma (HCC) receiving durvalumab and tremelimumab (Dur/Tre).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 167 patients treated with Dur/Tre between March 2023 and March 2024 in Japanese hospitals were included in this retrospective multicentre study. Patients were divided into two groups based on pre-treatment serum CRP levels: the low-CRP group (< 1 mg/dL, <i>n</i> = 106) and the high-CRP group (≥ 1 mg/dL, <i>n</i> = 61).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median age of the cohort was 74.0 years (interquartile range, 67.5–79.5), and 139 patients (83.2%) were male. The median progression-free survival (PFS) was 3.6 months (95% CI: 2.6–5.4) in the low-CRP group and 2.4 months (95% CI: 1.9–4.1) in the high-CRP group, with statistical significance (<i>p</i> = 0.02). The median overall survival (OS) was not reached in the low-CRP group, with a 1-year survival rate of 64.7% (95% CI: 49.0–76.7), while it was 7.9 months (95% CI: 5.8–11.8) in the high-CRP group. The low-CRP group demonstrated significantly better survival outcomes compared to the high-CRP group (<i>p</i> < 0.001). Multivariate analysis identified serum CRP level as an independent predictive factor for both PFS and OS (<i>p</i> = 0.04 and < 0.001, respectively). No significant differences in immune-related adverse events were observed between the two groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Serum CRP may serve as a prognostic biomarker in HCC patients receiving Dur/Tre, with a potential association with treatment efficacy.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 7","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70192","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

This study aimed to evaluate the therapeutic efficacy and prognostic significance of C-reactive protein (CRP) in patients with advanced hepatocellular carcinoma (HCC) receiving durvalumab and tremelimumab (Dur/Tre).

Methods

A total of 167 patients treated with Dur/Tre between March 2023 and March 2024 in Japanese hospitals were included in this retrospective multicentre study. Patients were divided into two groups based on pre-treatment serum CRP levels: the low-CRP group (< 1 mg/dL, n = 106) and the high-CRP group (≥ 1 mg/dL, n = 61).

Results

The median age of the cohort was 74.0 years (interquartile range, 67.5–79.5), and 139 patients (83.2%) were male. The median progression-free survival (PFS) was 3.6 months (95% CI: 2.6–5.4) in the low-CRP group and 2.4 months (95% CI: 1.9–4.1) in the high-CRP group, with statistical significance (p = 0.02). The median overall survival (OS) was not reached in the low-CRP group, with a 1-year survival rate of 64.7% (95% CI: 49.0–76.7), while it was 7.9 months (95% CI: 5.8–11.8) in the high-CRP group. The low-CRP group demonstrated significantly better survival outcomes compared to the high-CRP group (p < 0.001). Multivariate analysis identified serum CRP level as an independent predictive factor for both PFS and OS (p = 0.04 and < 0.001, respectively). No significant differences in immune-related adverse events were observed between the two groups.

Conclusions

Serum CRP may serve as a prognostic biomarker in HCC patients receiving Dur/Tre, with a potential association with treatment efficacy.

查看原文本刊更多论文

血清CRP水平对Durvalumab和Tremelimumab治疗晚期HCC的临床影响：一项多中心研究

目的评价c反应蛋白（CRP）在接受durvalumab和tremelimumab （Dur/Tre）治疗的晚期肝细胞癌（HCC）患者中的疗效及预后意义。方法回顾性多中心研究于2023年3月至2024年3月在日本医院接受Dur/Tre治疗的167例患者。根据治疗前血清CRP水平将患者分为两组：低CRP组（≤1mg /dL, n = 106）和高CRP组（≥1mg /dL, n = 61）。结果队列中位年龄为74.0岁（四分位间距67.5 ~ 79.5），男性139例（83.2%）。低crp组中位无进展生存期（PFS）为3.6个月（95% CI: 2.6 ~ 5.4），高crp组中位无进展生存期（PFS）为2.4个月（95% CI: 1.9 ~ 4.1），差异均有统计学意义（p = 0.02）。低crp组未达到中位总生存期（OS）， 1年生存率为64.7% (95% CI: 49.0-76.7)，而高crp组为7.9个月（95% CI: 5.8-11.8）。与高crp组相比，低crp组的生存结果明显更好（p < 0.001）。多变量分析发现血清CRP水平是PFS和OS的独立预测因素（p = 0.04和<； 0.001）。两组之间免疫相关不良事件无显著差异。结论血清CRP可作为HCC患者接受Dur/Tre治疗的预后生物标志物，与治疗效果有潜在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.